ERN1 and cancer: Since activities of kinase and endoribonuclease of IRE1α can be selectively controlled by distinct classes of adenosine triphosphate (ATP)-competitive inhibitors (78), it is expected that regulation of pathway might be a therapeutic strategy for cancer.